Hepatitis C Clinical Trials

Yes. Many current trials focus on people who have achieved sustained virologic response (SVR) but still have liver fibrosis, cirrhosis, or elevated liver cancer risk. These studies test treatments to reverse liver damage or prevent hepatocellular carcinoma. Your post-cure liver health status will determine which trials you may be eligible for.

Yes, treatment-experienced patients are a key focus of current research. Trials are testing salvage regimens with new drug combinations specifically designed for people whose virus did not respond to first-line DAA therapy. These studies often target specific resistance-associated substitutions that caused prior treatment failure.

Not necessarily. The research team will conduct genotype testing during the screening process if it is relevant to the study. Many newer trials use pan-genotypic approaches that work across all genotypes. Having prior lab results available can speed up the screening process but is not usually required.

Not in most modern hepatitis C trials. Researchers recognize that people who inject drugs are disproportionately affected by hepatitis C and must be included in clinical research. Some trials are specifically designed for this population. Individual study criteria vary, so check each trial listing or ask the research coordinator directly.

Hepatitis C vaccine research is ongoing but still in early stages. Unlike hepatitis A and B, no approved vaccine exists for hepatitis C due to the virus mutating rapidly. Several vaccine candidates are in Phase 1 and Phase 2 trials. These prevention trials typically enroll HIV-negative individuals at higher risk of hepatitis C exposure.